首页> 美国卫生研究院文献>Antimicrobial Agents and Chemotherapy >Comparison of norfloxacin and nalidixic acid for treatment of dysentery caused by Shigella dysenteriae type 1 in adults.
【2h】

Comparison of norfloxacin and nalidixic acid for treatment of dysentery caused by Shigella dysenteriae type 1 in adults.

机译:诺氟沙星和萘啶酸治疗成人痢疾志贺氏菌引起的痢疾的比较。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

A severe epidemic of dysentery began late in 1979 in northeast Zaire and spread to Rwanda, Burundi, and Tanzania. The epidemic strain is a multiply resistant Shigella dysenteriae type 1, which acquired resistance against trimethoprim and more recently against nalidixic acid in the course of the epidemic. A comparative open trial in Rwandan adults with Shiga dysentery involved 18 patients treated with norfloxacin at 400 mg twice daily and 12 patients treated with nalidixic acid at 1 g three times daily for 5 days. All isolates showed in vitro susceptibility to both drugs. Though norfloxacin eliminated Shigella organisms from stools more rapidly than nalidixic acid, its clinical superiority did not reach the level of significance. Norfloxacin is a promising drug and is more effective than nalidixic acid in the treatment of multiresistant shigellosis.
机译:痢疾的严重流行于1979年底在扎伊尔东北部开始,并蔓延到卢旺达,布隆迪和坦桑尼亚。该流行病菌株是多重耐药性痢疾志贺氏菌1型,在流行过程中获得了对甲氧苄氨嘧啶和最近对萘啶酸的耐药性。在卢旺达患有志贺氏痢疾的成年人中进行的一项比较性开放试验涉及18例患者,每天两次接受诺氟沙星400 mg的治疗,每天12例患者,每天1次服用萘啶酸的3次,连续5天。所有分离株均显示出对两种药物的体外敏感性。尽管诺氟沙星比粪便中的纳豆酸更快地清除了粪便中的志贺氏菌,但其临床优势尚未达到显着水平。诺氟沙星是一种有前途的药物,在多耐药性志贺菌病的治疗中比萘啶酸更有效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号